210 related articles for article (PubMed ID: 31545416)
1. Identification of new cancer stem cell markers and signaling pathways in HER‑2‑positive breast cancer by transcriptome sequencing.
Feng L; Huang S; An G; Wang G; Gu S; Zhao X
Int J Oncol; 2019 Nov; 55(5):1003-1018. PubMed ID: 31545416
[TBL] [Abstract][Full Text] [Related]
2. POPDC1 is suppressed in human breast cancer tissues and is negatively regulated by EGFR in breast cancer cell lines.
Amunjela JN; Tucker SJ
Cancer Lett; 2017 Oct; 406():81-92. PubMed ID: 28807821
[TBL] [Abstract][Full Text] [Related]
3. The expression of stem cell protein Piwil2 and piR-932 in breast cancer.
Zhang H; Ren Y; Xu H; Pang D; Duan C; Liu C
Surg Oncol; 2013 Dec; 22(4):217-23. PubMed ID: 23992744
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
6. STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession.
Xie J; Yang Y; Sun J; Jiao Z; Zhang H; Chen J
Clin Breast Cancer; 2019 Feb; 19(1):e195-e207. PubMed ID: 30253922
[TBL] [Abstract][Full Text] [Related]
7. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
8. STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.
Yang Q; Ji G; Li J
Cancer Biol Ther; 2020; 21(3):278-291. PubMed ID: 31696760
[TBL] [Abstract][Full Text] [Related]
9. Expression profiling of RTL1 in human breast cancer tissues and cell lines.
Mahmoudi AR; Ghods R; Madjd Z; Abolhasani M; Saeednejad Zanjani L; Safaei M; Balaei Goli L; Vafaei S; Katouzian L; Soltanghoraei H; Shekarabi M; Zarnani AH
Exp Mol Pathol; 2021 Aug; 121():104654. PubMed ID: 34087231
[TBL] [Abstract][Full Text] [Related]
10. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
12. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
13. Wnt pathway activity in breast cancer sub-types and stem-like cells.
Lamb R; Ablett MP; Spence K; Landberg G; Sims AH; Clarke RB
PLoS One; 2013; 8(7):e67811. PubMed ID: 23861811
[TBL] [Abstract][Full Text] [Related]
14. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
15. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
[TBL] [Abstract][Full Text] [Related]
17. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
19. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
Droeser RA; Obermann EC; Wolf AM; Wallner S; Wolf D; Tzankov A
Clin Breast Cancer; 2013 Aug; 13(4):264-70. PubMed ID: 23829892
[TBL] [Abstract][Full Text] [Related]
20. Role of microRNAs in the regulation of breast cancer stem cells.
Liu S; Clouthier SG; Wicha MS
J Mammary Gland Biol Neoplasia; 2012 Mar; 17(1):15-21. PubMed ID: 22331423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]